Therapeutic potential of TACI-Ig in treatment of arthritis

Context

BLyS (BAFF, TALL-1, THANK, zTNF4) and APRIL are members of the TNF family that modulate B-cell activation and survival. TACI and BCMA are two previously characterized receptors for BLyS that also bind to APRIL. Transgenic animals that overexpress BLyS develop symptoms similar to SLE. Recombinant TACI-Ig decreases disease severity and frequency in SLE susceptible mice, thus, implicating BLyS in the development of SLE and, perhaps, autoimmune disorders in general. Elevated levels of BLyS are also observed in the serum of RA patients. In this study, the effect of TACI-Ig on arthritis in a mouse model of CIA was examined.

Significant findings

Injection of TACI-Ig prior to the second collagen injection in male DBA/1 mice delayed the onset and decreased the severity of disease and decreased the percentage of animals that developed CIA. To determine the effects of TACI-Ig in a manner resembling treatment of existing disease, TACI-Ig treatment initiation was delayed until 7 days after the second injection, when 52% of the animals developed anticollagen antibodies and demonstrated signs of inflammation. Again, TACI-Ig treatment inhibited disease progression, decreasing both inflammation and the percentage of animals that progressed to established disease. Thus, TACI-Ig is a novel therapeutic agent for autoimmune disease, including arthritis, with great clinical potential. In both TACI-Ig transgenic and BLyS-deficient mice decreases in mature B cells were observed, implicating BLyS in B-cell development. However, TACI-Ig injections into normal mice caused a significant decrease in the number of mature B cells, although immature B-cell populations were unaffected.

Comments

The use of TACI-Ig to inhibit the progression of CIA after the onset of inflammation and generation of anticollagen antibodies demonstrates its clinical potential in treating RA and other autoimmune disorders. Given previous implications for BLyS in autoimmune disease, the mechanism of action of TACI-Ig is presumably inhibition of BLyS, and not its other ligand, APRIL. The authors suggest that BLyS is not directly involved in B-cell development, but in maintaining homeostasis of mature B-cell populations. Presumably, TACI-Ig exerts its effects in murine models of RA through deletion of mature, autoreactive B cells (although this was not explicitly examined). Recently, a novel receptor for BLyS has been cloned that does not bind APRIL (see Additional information [1]); future work will elucidate whether this new receptor is the relevant target in TACI-Ig inhibition of CIA. Another group generated a BLyS-deficient animal with similar phenotype (see Additional information [2]).

Methods

CIA model, gene targeting, knockout mice, transgenic mice